EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells

Yang Wu, Sophie Franzmeier iD, Friederike Liesche-Starnecker iD, Jürgen Schlegel iD

Cells · 25.10.2023 · 12 (21) · 2522

DOI: 10.3390/cells12212522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 25.10.2023. Verfasst von Yang Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, Institute of Pathology, School of Medicine, Technical University Munich, 81675 Munich, Germany. Hauptthemen laut MEDLINE: Ferroptosis, Glioblastoma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temozolomide (TMZ) is standard treatment for glioblastoma (GBM); nonetheless, resistance and tumor recurrence are still major problems. In addition to its association with recurrent GBM and TMZ resistance, ALDH1A3 has a role in autophagy-dependent ferroptosis activation. In this study, we treated TMZ-resistant LN229 human GBM cells with the ferroptosis inducer RSL3. Remarkably, TMZ-resistant LN229 clones were also resistant to ferroptosis induction, although lipid peroxidation was induced by RSL3. By using Western blotting, we were able to determine that ALDH1A3 was down-regulated in TMZ-resistant LN229 cells. Most intriguingly, the cell viability results showed that only those clones that up-regulated ALDH1A3 after TMZ withdrawal became re-sensitized to ferroptosis induction. The recovery of ALDH1A3 expression appeared to be regulated by EGFR-dependent PI3K pathway activation since Akt was activated only in ALDH1A3 high clones. Blocking the EGFR signaling pathway with the EGFR inhibitor AG1498 decreased the expression of ALDH1A3. These findings shed light on the potential application of RSL3 in the treatment of glioblastoma relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisGlioblastomaHumansCell Line, TumorDrug Resistance, NeoplasmErbB ReceptorsNeoplasm Recurrence, LocalPhosphatidylinositol 3-KinasesTemozolomideAldehyde Oxidoreductases

Stichwörter der Autor:innen

ALDH1ferroptosisglioblastomatherapeutic interventionstherapy resistance

Substanzen

ErbB ReceptorsPhosphatidylinositol 3-KinasesTemozolomidealdehyde dehydrogenase (NAD(P)+)Aldehyde Oxidoreductases

Autor:innen und Institutionen

  • Department of Neuropathology, Institute of Pathology, School of Medicine, Technical University Munich, 81675 Munich, Germany.
  • Department of Neuropathology, Institute for Animal Pathology, Ludwig-Maximilians-University Munich, 80539 Munich, Germany.
  • Pathology, Medical Faculty, University of Augsburg, 81656 Augsburg, Germany.

ORCID-Profile: Sophie Franzmeier, Friederike Liesche-Starnecker, Jürgen Schlegel

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Wu, Y., Franzmeier, S., Liesche-Starnecker, F., & Schlegel, J. (2023). Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells. Cells, 12(21), 2522. https://doi.org/10.3390/cells12212522

Vancouver

Wu Y, Franzmeier S, Liesche-Starnecker F, Schlegel J. Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells. Cells. 2023;12(21):2522. doi:10.3390/cells12212522

BibTeX
@article{Wu2023,
  author = {Wu, Yang and Franzmeier, Sophie and Liesche-Starnecker, Friederike and Schlegel, Jürgen},
  title = {Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {21},
  pages = {2522},
  doi = {10.3390/cells12212522}
}
Kostenlos starten →